AstraZeneca: licensing agreement for skin diseases
(CercleFinance.com) - AstraZeneca has signed a licensing agreement with Boston-based biotechnology firm Pyramid Biosciences for the development of new drugs for dermatological and inflammatory diseases, including psoriasis.
The deal focuses on the commercialization rights to a novel Tropomyosin receptor kinase modulator, PBI-100, that can control the key signaling pathways responsible for a patient's symptoms.
Under the agreement, Pyramid Biosciences will licence exclusive rights to develop and commercialize the compound globally.
The financial terms of the agreement were not disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The deal focuses on the commercialization rights to a novel Tropomyosin receptor kinase modulator, PBI-100, that can control the key signaling pathways responsible for a patient's symptoms.
Under the agreement, Pyramid Biosciences will licence exclusive rights to develop and commercialize the compound globally.
The financial terms of the agreement were not disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.